scholarly journals Adjunctive therapy with inhaled nitric oxide for severe acute chest syndrome in patients with sickle cell disease

2015 ◽  
Vol 41 (12) ◽  
pp. 2213-2215
Author(s):  
Hermann Wrigge ◽  
Eduardo L. V. Costa ◽  
Thilo Busch
1999 ◽  
Vol 27 (11) ◽  
pp. 2563-2568 ◽  
Author(s):  
Kevin J. Sullivan ◽  
Salvatore R. Goodwin ◽  
Jennifer Evangelist ◽  
Robert D. Moore ◽  
Paulette Mehta

Anemia ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-15 ◽  
Author(s):  
Kathryn Blake ◽  
John Lima

Objective. To review issues related to asthma in sickle cell disease and management strategies.Data Source. A systematic review of pertinent original research publications, reviews, and editorials was undertaken using MEDLlNE, the Cochrane Library databases, and CINAHL from 1947 to November 2010. Search terms were [asthma] and [sickle cell disease]. Additional publications considered relevant to the sickle cell disease population of patients were identified; search terms included [sickle cell disease] combined with [acetaminophen], [pain medications], [vitamin D], [beta agonists], [exhaled nitric oxide], and [corticosteroids].Results. The reported prevalence of asthma in children with sickle cell disease varies from 2% to approximately 50%. Having asthma increases the risk for developing acute chest syndrome , death, or painful episodes compared to having sickle cell disease without asthma. Asthma and sickle cell may be linked by impaired nitric oxide regulation, excessive production of leukotrienes, insufficient levels of Vitamin D, and exposure to acetaminophen in early life. Treatment of sickle cell patients includes using commonly prescribed asthma medications; specific considerations are suggested to ensure safety in the sickle cell population.Conclusion. Prospective controlled trials of drug treatment for asthma in patients who have both sickle cell disease and asthma are urgently needed.


2008 ◽  
Vol 56 (8) ◽  
pp. 1023-1027 ◽  
Author(s):  
Wun-Ling Chang ◽  
Lalaine M. Corate ◽  
James M. Sinclair ◽  
Henri C. van der Heyde

ABSTRACTA 27-year-old female with sickle cell disease (HbSS) was admitted presenting with severe bone pain and fever. She refused blood transfusions throughout her hospital stay for religious reasons. During the first 9 days of admission, the patient's clinical presentation became worse despite antibiotic coverage. The patient exhibited pulmonary infiltrates and mild hypertension, increased pain, fever, tachycardia, and decreased hematocrit. After day 8 of admission, her laboratory findings and clinical presentation indicated that her disease was markedly worse. With the patient's consent, inhaled nitric oxide therapy (iNO = 40 ppm) was initiated and continued for 3.2 days. After a full day of iNO therapy, the clinical improvement was limited to temperature normalization and stabilization of her hemoglobin levels. After 2 more days of iNO therapy, her multiple clinical complications of sickle cell disease improved markedly and she was discharged 3 days after completion of the iNO treatment. The complications of NO therapy, such as methemoglobulinemia or decreased blood pressure, were not detected during the iNO therapy. Although limited to a single individual, we propose that our anecdotal experience suggests that iNO therapy may (i) need to be continuous for several days to provide improved benefits, (ii) treat several of sickle cell complications besides pain, and (iii) exhibit few complications. These proposals need to be confirmed in clinical trials.


Sign in / Sign up

Export Citation Format

Share Document